Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2013

View Archived Issues

International trial of rhNGF begins in the treatment of neurotrophic keratitis

Roche presents potential predictivity of preclinical cancer models

177Lu-J-591 shows promising antitumor activity at the MTD of 70 mCi/m2

Shin Nippon Biomedical Laboratories and Kyoto University enter agreement

Mylan enters generic insulin agreement with Biocon

Antitumor activity demonstrated for TRAIL-inducing compound TIC-10

Dako launches nontoxic FISH assay for cancer diagnosis in U.S.

Third Rock Ventures launches new company with a focus on cancer immunotherapy

Emory University and Health Research patent new TAK1 inhibitors

Novartis presents final results of a phase II study of dovitinib in urothelial cancer

FDA grants orphan drug status to OSE-2101

GlaxoSmithKline presents novel Lp-PLA2 inhibitors

Nerviano Medical Sciences divulges new protein kinase inhibitors

Novel c-Kit inhibitors presented by AB Science

Researchers at Allergan synthesize new alpha-adrenoceptor agonists

Phase II results for linsitinib in mCRPC presented

Livalo OD tablets approved in Japan for hypercholesteremia

FDA advisory committee recommends approval of contrast agent Dotarem

FDA accepts Oralair BLA for review

Piromelatine shows promise in phase II insomnia trial

Verastem compounds target cancer stem cells

FDA approves Zortress in new indication

Scientists at Grunenthal prepare novel TRPV1 ligands

Lilly and QIAGEN to collaborate on companion diagnostics

FDA grants priority review to dolutegravir NDA

Phase II trial of Cogane in Parkinson's disease misses endpoints

FDA approves Argus II Retinal Prosthesis System for patients with advanced retinitis pigmentosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...